ArticleTransfusion2025
Expanding beyond trauma: Characterizing low titer group O whole blood (LTOWB) use in children requiring massive transfusion protocol activation.
Article in Transfusion, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionData regarding low titer group O whole blood (LTOWB) use for hemostatic resuscitation is largely derived from trauma cohorts; studies regarding its use in uninjured pediatric patients are lacking.
methodsThe blood bank database from a single academic pediatric hospital with a massive transfusion protocol (MTP) allowing the use of LTOWB for any severe bleeding etiology was queried between 2016 and 2023. Pediatric (age <18 years) recipients of LTOWB were included; injured children were excluded. Data recorded included demographics, bleeding etiology, blood volumes, mortality (24-h and in-hospital), organ dysfunction, and, when available, posttransfusion biochemical markers of hemolysis.
resultsOf 112 recipients of LTOWB, 16 met inclusion criteria. Median (IQR) age was 13 years (8-16) and 8/16 (50%) were male. MTP was most often activated on the day of admission (median (IQR) = day 0 (0-1)), and the bleeding etiology was variable, including perioperative (8/16; 50%), gastrointestinal bleed (5/16; 31%), and extracorporeal membrane oxygenation (ECMO) cannulation (3/16; 19%). The median (IQR) weight-adjusted volume of LTOWB transfused was 19 (10-26) mL/kg, and most children (13/16; 81%) received component blood products in addition to LTOWB. The 24-h mortality rate was 25% (4/16) and in-hospital mortality was 44% (7/16). The most common complication was AKI (10/16; 63%). There were no significant differences in biochemical hemolysis markers between group O (n = 7) and non-group O (n = 9) LTOWB recipients at any time point (p = .07-.99).
conclusionsLTOWB use was feasible in the resuscitation of children with various bleeding etiologies requiring massive transfusion. Larger prospective investigations are needed to inform guidelines for optimal use in this cohort. LEVEL OF EVIDENCE: Retrospective Observational Study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.